CLONAPAM TABLET

国: カナダ

言語: 英語

ソース: Health Canada

有効成分:

CLONAZEPAM

から入手可能:

BAUSCH HEALTH, CANADA INC.

ATCコード:

N03AE01

INN（国際名）:

CLONAZEPAM

投薬量:

1MG

医薬品形態:

TABLET

構図:

CLONAZEPAM 1MG

投与経路:

ORAL

パッケージ内のユニット:

100/500

処方タイプ:

Targeted (CDSA IV)

治療領域:

BENZODIAZEPINES

製品概要:

Active ingredient group (AIG) number: 0111558004; AHFS:

認証ステータス:

APPROVED

承認日:

2021-03-10

製品の特徴

PRODUCT MONOGRAPH
CLONAPAM
®
Clonazepam Tablets, USP
0.5 mg. 1 mg, and 2 mg
ANTICONVULSANT
BAUSCH HEALTH, CANADA INC.
DATE OF REVISION:
2150 St-Elzear Blvd. West
September 1, 2021
Laval, Quebec
H7L 4A8
Control #: 253836
_T/C_
_CLONAPAM_
_®_
_ Product Monograph Page 2 of 34_
_ _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.......................................................... 3
SUMMARY PRODUCT INFORMATION
............................................................................
3
INDICATIONS AND CLINICAL USE
.................................................................................
3
CONTRAINDICATIONS
.....................................................................................................
4
WARNINGS AND PRECAUTIONS
.....................................................................................
4
ADVERSE
REACTIONS.....................................................................................................12
DRUG INTERACTIONS
.....................................................................................................14
DOSAGE AND ADMINISTRATION
..................................................................................16
OVERDOSAGE
..................................................................................................................17
ACTION AND CLINICAL
PHARMACOLOGY..................................................................19
STORAGE AND STABILITY
.............................................................................................20
SPECIAL HANDLING INSTRUCTIONS
............................................................................20
DOSAGE FORMS, COMPOSITION AND PACKAGING
...................................................21
PART II: SCIENTIFIC
INFORMATION...............................................................................
22
PHARMACEUTICAL INFORMATION
..............................................................................22
CLINICAL TRIALS
...................................................